Equities analysts expect Nevro Corp (NYSE:NVRO) to post $88.57 million in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Nevro’s earnings, with the highest sales estimate coming in at $91.20 million and the lowest estimate coming in at $87.00 million. Nevro posted sales of $68.44 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 29.4%. The firm is scheduled to issue its next earnings report on Monday, May 14th.
On average, analysts expect that Nevro will report full year sales of $88.57 million for the current year, with estimates ranging from $403.00 million to $407.60 million. For the next financial year, analysts anticipate that the company will post sales of $480.83 million per share, with estimates ranging from $459.23 million to $502.50 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Nevro.
Nevro (NYSE:NVRO) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported ($0.15) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.01). Nevro had a negative return on equity of 15.01% and a negative net margin of 11.22%. The firm had revenue of $97.96 million during the quarter, compared to analysts’ expectations of $96.87 million. During the same period last year, the company earned ($0.34) earnings per share. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year.
A number of analysts recently weighed in on NVRO shares. Leerink Swann reissued an “outperform” rating and issued a $110.00 price objective (up from $105.00) on shares of Nevro in a research report on Tuesday, November 7th. Northland Securities reissued a “buy” rating and issued a $96.00 price objective on shares of Nevro in a research report on Tuesday, November 7th. Canaccord Genuity reduced their price objective on shares of Nevro from $120.00 to $110.00 and set a “buy” rating on the stock in a research report on Tuesday, November 7th. BidaskClub lowered shares of Nevro from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $100.00 price objective on shares of Nevro in a research report on Thursday, December 14th. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $99.25.
In other Nevro news, CFO Andrew H. Galligan sold 7,000 shares of the company’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $80.10, for a total value of $560,700.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Wilfred E. Jaeger sold 14,458 shares of the company’s stock in a transaction dated Tuesday, February 27th. The stock was sold at an average price of $83.28, for a total transaction of $1,204,062.24. Following the completion of the transaction, the director now owns 1,518 shares in the company, valued at $126,419.04. The disclosure for this sale can be found here. Insiders sold a total of 31,458 shares of company stock worth $2,569,562 over the last 90 days. Insiders own 9.10% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC bought a new position in Nevro in the 4th quarter worth about $900,000. Glenmede Trust Co. NA bought a new position in Nevro in the 4th quarter worth about $237,000. Macquarie Group Ltd. grew its stake in Nevro by 40.8% in the 4th quarter. Macquarie Group Ltd. now owns 33,760 shares of the medical equipment provider’s stock worth $2,331,000 after acquiring an additional 9,782 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of Nevro by 49.3% during the fourth quarter. Teachers Advisors LLC now owns 180,265 shares of the medical equipment provider’s stock valued at $12,445,000 after purchasing an additional 59,505 shares in the last quarter. Finally, HBK Investments L P bought a new position in shares of Nevro during the fourth quarter valued at approximately $255,000.
Nevro (NYSE:NVRO) traded up $2.08 during trading on Friday, reaching $82.73. 365,923 shares of the company were exchanged, compared to its average volume of 390,507. The company has a debt-to-equity ratio of 0.58, a current ratio of 7.61 and a quick ratio of 5.91. Nevro has a 12 month low of $65.00 and a 12 month high of $97.70. The stock has a market cap of $2,390.54, a price-to-earnings ratio of -64.64 and a beta of -0.51.
COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Expect Nevro Corp (NVRO) Will Announce Quarterly Sales of $88.57 Million” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thelincolnianonline.com/2018/03/14/zacks-brokerages-expect-nevro-corp-nvro-will-announce-quarterly-sales-of-88-57-million.html.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.